A booster dose of an inactivated vaccine increases neutralizing antibodies and T cell responses against SARS-CoV-2.

Bárbara M Schultz¹,#, Felipe Melo-González¹,#, Luisa F Duarte¹,#, Nicolás MS Gálvez¹,#, Gaspar A Pacheco¹,#, Jorge A Soto¹,#, Roslye V Berrios-Rojas¹,², Liliana A González¹,², Daniela Moreno-Tapia¹,², Daniela Rivera-Pérez¹,², Guillermo Hoppe-Elsholz¹,², Carolina Iturriaga³, Mariana Ríos¹,², Omar P Vallejos¹,², Marcela Urzua³, Yaneisi Vázquez¹,², María S Navarrete⁴, Álvaro Rojas⁴, Daniela Weiskopf⁵, Alessandro Sette⁵,⁶, Gang Zeng⁷, Weining Meng⁷, CoronaVac03CL Study Group, José V González-Aramundiz⁸, Pablo A González¹,², Katia Abarca¹,³, Alexis M Kalergis*¹,²,⁹, Susan M Bueno*¹,²

Affiliations:
¹Millennium Institute on Immunology and Immunotherapy, Santiago, Chile. ²Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. ³Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. ⁴Departamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. ⁵Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. ⁶Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. ⁷Sinovac Biotech, Beijing, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
8Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile. 9Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

*These authors contributed equally to this work.

*Corresponding authors.

Keywords:

CoronaVac; Phase 3 clinical trial; SARS-CoV-2; COVID-19; Vaccines, Booster, Third dose.
Abstract

Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. CoronaVac® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO) to prevent COVID-19 that has safety and immunogenicity profiles described in different clinical trials. We previously reported an increase in levels of neutralizing antibodies two- and four-weeks after administering two doses of CoronaVac® in a two-week interval (0-14 day) vaccination schedule, as compared to pre-immune sera in adults in the Chilean population that are participating in a phase 3 clinical trial. Here we report the levels of antibodies directed against the Receptor Binding Domain of the SARS-CoV-2 spike protein comparing their neutralizing capacities and the cellular response at five months after the second dose and four weeks after a booster (third) dose in volunteers immunized with two doses of CoronaVac® in a four-week interval (0-28 day) vaccination schedule. We observed a decrease in the levels of anti-SARS-CoV-2 antibodies with neutralizing capacities five months after the second dose (GMU 39.0 95% confidence interval (CI) (32.4-47.0), which increased up to 12 times at four weeks after the booster dose (GMU 499.4, 95% CI=370.6-673.0). Equivalent results were observed in adults aged 18-59 years old and individuals ≥60 years old. In the case of cellular response, we observed that activation of specific CD4+ T cell increases in time and reaches its maximum at four weeks after the booster dose in both groups. Our results support the notion that a booster dose of the SARS-CoV-2 inactivated vaccine increases the levels of neutralizing antibodies and the specific cellular response in adults of both groups, which is likely to boost the protective capacity of these vaccines against COVID-19.
Introduction

The ongoing pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has promoted the rapid development of safe, immunogenic, and effective vaccines against SARS-CoV-2 to be used by the general population, which have successfully reduced the transmission of the disease burden. CoronaVac® is an inactivated SARS-CoV-2 vaccine developed by Sinovac Life Sciences Co., Ltd. (Beijing, China) and is among the current vaccines approved by the WHO to combat COVID-19 [1,2]. Phase 1 and 2 clinical trials in China demonstrated that this vaccine induces cellular and humoral response upon immunization [3–5]. Furthermore, an ongoing phase 3 clinical trial in Chile has described that two- and four-weeks after the second dose of CoronaVac® there is an increase in the levels of IgG and neutralizing antibodies in adults aged 18-59 years old and ≥ 60 years old [5][6]. In addition, the vaccination promotes the activation of the cellular immune response against SARS-CoV-2 antigens in a 0-14 immunization schedule [5], being an effective vaccine to prevent COVID-19 [7,8]. In Chile, 91.5% of the target population has received the first vaccine dose, and 88.7% were fully vaccinated in October 2021 in a 0-28 vaccination schedule [9]. Although neutralizing antibody titers present in the serum of vaccinated people are thought to be highly predictive of immune protection [10], these titers decrease in time [6,11,12]. Besides this, vaccine-induce antibodies have lower levels of neutralization against highly transmissible variants of the virus as compared to the original vaccine strain, potentially decreasing the effectiveness of these vaccines as new variants emerge [13,14]. For these reasons, the use of booster doses was
approved in adults in August 2021 in Chile, in high-risk populations and subjects with more than five months after the second dose applied in a 0-28-day vaccination schedule [15]. Notably, a previous study performed in adults between 18-59 years old demonstrates that a booster dose of CoronaVac®, applied after six months to individuals previously receiving two doses of this vaccine, increases the levels of antibodies 3-5-fold as compared to those levels observed four weeks after the second dose [12]. Here, we further extend these results by reporting the levels of neutralizing antibodies and specific T cells against SARS-CoV-2 in adults ≥18 years old who participated in phase 3 clinical trial carried out in Chile, who were vaccinated in a 0-28-day vaccination schedule with a booster (third) dose five months after the second dose.

**Materials and methods**

**Patients and sample collection**

Blood samples were obtained from volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov #NCT04651790) carried out in Chile starting January 2021. The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Católica de Chile (#200708006). Trial execution was approved by the Chilean Public Health Institute (#24204/20) and was conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki [16], and local regulations. Informed consent was obtained from all volunteers upon enrollment. Volunteers receive two doses of CoronaVac® (3 µg or 600SU of inactivated SARS-
CoV-2 inactivated along with alum adjuvant) in a four-week interval (0–28-day immunization schedule) and then a booster dose five months after the second dose. A complete inclusion and exclusion criteria list has been reported. On November 11st 2021, one hundred and eighty-six volunteers in the immunogenicity branch received the booster dose, and the antibodies against RBD with neutralizing capacities were quantified in 77 volunteers who had completed all their previous visits in one of the centers of the study (Figure 1A). Blood samples were obtained from all the volunteers before administration of the first dose (pre-immune), two weeks after the second dose, four weeks after the second dose, twenty weeks (or five months) after the 2nd dose, and four weeks after the booster (third) dose (Figure 1B).

**Procedures**

To assess the presence of antibodies against RBD with neutralizing capacities, blood samples from 77 volunteers that had completed all their study visits, including one month after the booster dose of CoronaVac®, were measured. The neutralizing capacities of circulating antibodies were evaluated by a surrogate virus neutralization test (sVNT) (Genscript Cat#L00847-A). Samples were serially two-fold diluted starting at a 4-fold until reaching a 512-fold dilution. Assays were performed according to the instructions of the manufacturer and as reported previously [5]. Neutralizing antibody titers were determined as the last fold dilution with a cut-off over 30% of inhibition. Samples with a percentage of inhibition ≤30 at lowest dilution (1:4) were assigned as seronegative with a titer of 2. A sample was considered seropositive when its titer is higher than the pre-immune titer. The
percentage of inhibition was determined as: 100 * [OD450nm value of negative control - OD450nm value of sample] / [OD450nm of negative control]. A standard curve was used to plot the neutralization response in the samples as international units (IU) by using the WHO International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was prepared according to the manufacturer’s instructions [17]. Data were analyzed using a sigmoidal curve model with log concentration transformed, and the final concentration for each sample was the average of the product of the interpolated IU from the standard curve and the sample dilution factor required to achieve the OD450 value that falls within the linear range. Samples with undetermined concentration at the lowest dilution tested (1:4) were assigned the lower limit of quantification (16.4 IU). The Geometric Mean Units (GMU) or titers (GMT) were represented in the Figure 2 and Supplementary Figure 1, respectively, and Table 1 for comparisons among the visits.

ELISPOT and flow cytometry assays were performed to evaluate the cellular immune response, stimulating PBMCs with four Mega Pools (MPs) of peptides derived from the proteome of SARS-CoV-2 [18]: peptides from the S protein of SARS-CoV-2 (MP-S), the remaining proteins of the viral particle (excluding S protein peptides) (MP-R), and of peptides from the whole proteome of SARS-CoV-2 (MP-CD8-A and MP-CD8-B) [18]. Positives and negative controls were held for each assay. The number of Spot Forming cells (SFC) for IFN-γ and IL-4 were determined by ELISPOT, and the expression of Activation-Induced Markers (AIM+) by T cells was evaluated by flow cytometry. Assays were performed according to the instructions of the manufacturer and as reported previously [5]. Further details
on the ELISPOT assay, antibodies used for flow cytometry, and the respective protocols can be found in the **Supplementary Table 1**.

### Statistical analyses

Statistical differences for the immunogenicity results considered one-way ANOVAs mixed-effects analysis for comparisons between the booster dose and the other visits performed on the logarithms of the data. The significance level was set at 0.05 for all the analyses. All data were analyzed with GraphPad Prism 9.0.1.

### Results

One hundred and twenty-nine volunteers from the immunogenicity branch, who received the booster dose of the CoronaVac®, were included in this study. The first dose of the vaccine was inoculated from January - March of 2021, and the second dose was inoculated 28 days after the first one. Of them, we evaluated the neutralization capacity of circulating antibodies in 77 volunteers at five different time points indicated previously by sVNT and 33 of the same volunteers by ELISPOT and flow cytometry (**Figure 1B**).

In a normal 0-28-day schedule, the peak in the neutralizing capacity of the antibodies is reached at two weeks after the second dose (GMT 25.8, 95% CI=19.5-34.2) (**Supp. Figure 1**), decreasing at four weeks after the second dose (GMT 16.6, 95% CI=13.1-21.0). However, this neutralizing capacity present an important decreased five months after the second dose (GMT 3.5, 95% CI=3.0-4.1), which is in line with previous reports where the immunity against SARS-CoV-2 wanes six months after infection or vaccination [19,20]. As expected, after the

<table>
<thead>
<tr>
<th>Time Point</th>
<th>Neutralizing Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 weeks</td>
<td>GMT 25.8, 95% CI=19.5-34.2</td>
</tr>
<tr>
<td>4 weeks</td>
<td>GMT 16.6, 95% CI=13.1-21.0</td>
</tr>
<tr>
<td>5 months</td>
<td>GMT 3.5, 95% CI=3.0-4.1</td>
</tr>
</tbody>
</table>
booster dose, the neutralizing capacity of the antibodies increased even more than the one reported two weeks after the second dose. When we expressed the neutralizing capacity in arbitrary units of WHO (Figure 2) we observed that four weeks after the booster dose the neutralizing capacity increased more than 12-fold (GMU 499.4, 95% CI=370.6-673.0), as compared to the response at five months after the second dose (GMU 39.0 ± 32.4-47.0) and more than 2-fold as compared to the two weeks after the second dose (GMU 168.0 ± 126.8-222.5) (Figure 2A).

In adults between 18-59 years old, the neutralizing capacity of circulating antibodies reach its maximum four weeks after the booster dose (GMU 918.8 ± 623.4-1354) increasing more than 18-fold as compared to five months after the second dose (48.9 ± 37.6-63.5) and more than 4-fold as compared with two weeks after the second dose (GMU 220.2 ± 150.7-321.7) (Figure 2B). Seropositivity in this group reach 100% four weeks after the second dose (Table 1). 53.2% of the total volunteer analyzed here were adults ≥60 years. As seen in Figure 2C, the neutralizing capacity of circulating antibodies in this population also reached its peak at two weeks after the second dose (GMU 134.1 ± 89.2-201.6), decreasing at four weeks after the second dose (GMU 104.1 ± 71.8-151.0), and reaching its minimum at five months after the second dose (GMU 32.4 ± 25.1-41.8). In this group, we also observed an increase of more than 9-fold (GMU 300.5 ± 203.5-443.6) in the neutralizing capacity as compared to the response observed five months after the second dose (GMU 32.4). The seropositivity rate reached 49.4% in the total vaccine group and 35.7% in adults ≥60 years at five months after the second dose, which increased to 97.4% and 95.2%, respectively, four weeks after
the booster dose (Table 1). The seropositivity rate achieved at four weeks after the booster dose was the highest when compared with the other visits in the study in the total vaccinated group and in both groups analyzed.

Here we also report cellular responses following the booster dose of CoronaVac®, which is the first report of T cell responses in subjects vaccinated with a third dose of CoronaVac® to our knowledge. We did observe a significantly further increase in CD4⁺ T cell activation in both age groups following the third booster dose by flow cytometry (Figure 3) but we did not see a further increase in IFN-γ production upon stimulation with S and R MPs by ELISPOT at that time point (Supp. Figure 2). In addition, CD4⁺ T cell activation was still significantly increased 5 months after the 2nd dose in both age groups, suggesting that the 0-28 schedule can stimulate CD4⁺ cell responses over time. Moreover, we observed a significant increase in CD8⁺ AIM⁺ T cells following the third dose as compared to the time point 2 weeks following the second booster but not as compared to the pre-immune, whereas we did not observe a significant increase in IFN-γ upon stimulation with CD8 MPs at any time point, suggesting that CoronaVac promotes a reduced CD8⁺ T cell responses, even after a third dose. Thus, although humoral responses decrease over time following vaccination with CoronaVac®, CD4⁺ T cell responses stay significantly increased as compared to the pre-immune and the booster dose increases at least their activation.

Discussion
Although there was an adequate neutralization titer of anti-SARS-CoV-2 antibodies after two doses of CoronaVac® in the 0-28 schedule, with a 65.9% of effectiveness of preventing COVID-19 [8], the GMT waned in time, which was observed five months after the second dose. Due to this decrease in neutralizing capacity, a booster dose of CoronaVac® was evaluated in a clinical study in China, showing promising results in humoral immune responses [12]. The evaluation of the neutralization capacities reported here shows that after the booster dose, the neutralizing titers and seroconversion rates increase in the whole group even higher than two weeks after the second dose where was observed the peak in neutralization. As the neutralizing antibody titers correlate with protection against SARS-CoV-2 infection [10], these results likely imply a better outcome and protection against illness, as reported in previous studies performed in Israel that showed a decrease in the transmission and the severe disease by COVID-19 twelve or more days after booster inoculation [21]. Another study, performed with a booster dose of CoronaVac®, showed that an additional dose induced a good neutralization against SARS-CoV-2 WT strain and against variants four weeks after the booster dose, generating a long-lasting humoral response that was due to an enhancement of the memory immune response generated by B cells [22].

Adults ≥60 years old produced lower levels of antibodies with neutralizing capacities than the whole group during this study, which was also described in Bueno et al. [5]. This result is in line with previous data reported for a population vaccinated in Chile [6], a study among hospital workers who received two doses of CoronaVac® [23], and with the mRNA-1273 vaccine [24]. In this sense, our results are equivalent to those described in a phase 1/2 of the clinical trial with
CoronaVac®, showing that the neutralizing antibody titers in this group decrease at five months after the second dose and that a booster dose is required 6-8 months after the first vaccination to rapidly increased and steadily the neutralizing antibody titers [25].

In the case of cellular response, other studies have shown that Pfizer BNT162b2 and mRNA-1273 induce durable CD4⁺ T cell activation and cytokine production up to six months following vaccination but it remains to be elucidated whether CD4⁺ AIM⁺ T cells and cytokine production further increase following a booster dose of these vaccines [26,27]. In contrast to these vaccines, CoronaVac® delivers not only the Spike protein but other viral antigens, which may explain why vaccinated individuals still display CD4⁺ AIM⁺ T cells five months after the second dose, without even a third dose.

Our report shows that the booster dose with CoronaVac® in a 0-28 schedule induces a higher production of antibodies with neutralizing capacities, which are higher than the levels observed with 2- and 4-weeks after the first doses, generating an increased humoral response even in adults ≥60 years old. Besides this, our results suggest that a third dose of CoronaVac® supports CD4⁺ T cell activation, which may confer either protection or enhanced immune responses against the virus and prevent severe disease following SARS-CoV-2 exposure.

Limitations

This study presents some limitations, such as the reduced sample size for the assays. The assessment of total antibody response against Spike proteins and other SARS-CoV-2 proteins would also add additional information about the
humoral immune response against SARS-CoV-2 after the booster dose. Due to the limit of quantification of the technique, samples with undetermined concentration at the lowest dilution tested (1:4) were assigned the lower limit of quantification (16.4 IU) and other neutralization assays, such as conventional neutralization test, would confirm our results with the surrogate neutralization test used in this study.

**Funding**

This work was supported by: The Ministry of Health, Government of Chile supported the funding of the CoronaVac03CL Study; The Confederation of Production and Commerce (CPC), Chile, supported the funding of the CoronaVac03CL Study; the NIH NIAID under Contract No. 75N93021C00016 supports AS and Contract No. 75N9301900065 supports AS, DW. The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program ICN09_016 (former P09/016-F) supports SMB, KA, PAG and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG and AMK; SINOVAC contributed to this study with the investigational vaccine and experimental reagents.

**Competing interests**

ZG and MW are SINOVAC employees and contributed to the conceptualization of the study (clinical protocol and eCRF design) and did not participate in the analysis or interpretation of the data presented in the manuscript. All other authors declare no conflict of interest. A.S. is a consultant for Gritstone, Flow Pharma, Arcturus,
Immunoscope, CellCarta, OxfordImmunotech and Avalia. Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. All other authors declare no conflict of interest. The authors declare this study received the investigational product (placebo and vaccines) from the company SINOVAC Biotech. SINOVAC employees contributed to the conceptualization of the study (clinical protocol and eCRF design) but did not participate in either the analysis or interpretation of the data shown in this manuscript.

**Acknowledgments**

We would like to thank the support of the Ministry of Health, Government of Chile; Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile; and The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge Flores and Miren Iturriza-Gomara from PATH for their support on experimental design and discussion. We also thank the Vice Presidency of Research (VRI), the Direction of Technology Transfer and Development (DTD), the Legal Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are also grateful to the Administrative Directions of the School of Biological Sciences and the School of Medicine of the Pontificia Universidad Católica de Chile for their administrative support. Members of the CoronaVac03CL Study Group are listed in the Supplementary Appendix (SA). We would also like to thank the members of the independent data safety monitoring committee (members in the SA) for their oversight, and the subjects enrolled in the study for their
participation and commitment to this trial. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. Contract No. 75N9301900065 to A.S, D.W.
References


[25] Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. medRxiv [Internet]. 2021 [cited 2021 Oct 8];2021.08.03.21261544. Available from:
https://www.medrxiv.org/content/10.1101/2021.08.03.21261544v1.


Figure 1: Study profile, enrolled volunteers and cohort included in this study on October 31st, 2021. 77 of the 450 vaccinated individuals belonging to the immunogenicity branch of the clinical trial conducted in Chile were selected of one of the centers of the study (the CL1-Marcoleta) for immunogenicity assays. B.
Timeline of 0–28-day schedule of vaccination and booster (third) dose immunization. Text in red denotes timepoints at which blood draws occurred.
Figure 2: Quantification of circulating antibodies inhibiting the interaction between the S1-RBD and hACE2 in volunteers that received the booster dose twenty weeks after the second dose, in a 0–28-day vaccination schedule. Inhibiting antibody titer is expressed as international units by using a WHO standard. Results were obtained from 77 volunteers (A), 36 of them were adults between 18-59 years old (B), and 41 of them were ≥ 60 years old (C). Data is represented as the logarithm of the WHO arbitrary units. Numbers above the bars show the Geometric Mean units (GMU), the error bars indicate the 95% CI, and the number at the right represents the fold increase of the GMU after the third dose compared with the respective time. A One-Way ANOVA test assessed statistical differences to compare all times against 3rd dose + four weeks. ****p<0.0001.
Figure 3: Changes in activation-induced markers (AIMs) expression in T cells through flow cytometry upon stimulation with Mega Pools of peptides derived from SARS-CoV-2 in volunteers immunized with CoronaVac with the booster dose, given twenty weeks after the second dose, in a 0–28-day vaccination schedule. The percentage of activated CD4+ (AIM+ [OX40+, CD137+]) and CD8+ (AIM+ [CD69+, CD137+]) T cells was determined by flow cytometry, upon
stimulation for 24h with MP-S+R (A-C) and MP-CD8A+B (D-E) in samples obtained at pre-immune, two weeks after the 2nd dose, four weeks after the 2nd dose, twenty weeks the 2nd dose, and four weeks after the 3rd dose. Results were obtained from a total of 33 volunteers (A-D), 14 were of them were adults between 18-59 years old (B-E), and 19 of them were ≥ 60 years old (C-F). Data shown represent means ± 95%CI. Data from flow cytometry was normalized against DMSO and analyzed separately by One-way ANOVA with mixed effect analysis. *P<0.05; **p<0.005; ****p<0.0001.
# Table

Table 1: Seropositivity rates, Geometric Median Titer (GMT), and Geometric Median Units (GMU) of circulating neutralizing antibodies against SARS-CoV-2 RBD.

<table>
<thead>
<tr>
<th>Age group</th>
<th>Indicators</th>
<th>2w after 2nd dose</th>
<th>4w after 2nd dose</th>
<th>5m after 2nd dose</th>
<th>4w after 2nd dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Vaccine</td>
<td>Seropositivity n/N</td>
<td>72/77</td>
<td>73/77</td>
<td>38/77</td>
<td>75/77</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
<td>93.5</td>
<td>94.8</td>
<td>49.4</td>
<td>97.4</td>
</tr>
<tr>
<td></td>
<td>GMU</td>
<td>168.0</td>
<td>124.8</td>
<td>39.0</td>
<td>499.4</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>126.8-222.5</td>
<td>96.3-161.7</td>
<td>32.4-47.0</td>
<td>370.6-673.0</td>
</tr>
<tr>
<td></td>
<td>GMT</td>
<td>25.8</td>
<td>16.6</td>
<td>3.5</td>
<td>53.0</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>19.5-34.2</td>
<td>13.1-21.0</td>
<td>3.0-4.1</td>
<td>40.8-68.8</td>
</tr>
<tr>
<td>18-59</td>
<td>Seropositivity n/N</td>
<td>35/36</td>
<td>36/36</td>
<td>24/36</td>
<td>36/36</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
<td>97.2</td>
<td>97.2</td>
<td>66.7</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>GMU</td>
<td>220.2</td>
<td>155.0</td>
<td>48.9</td>
<td>918.8</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>150.7-321.7</td>
<td>108.0-222.6</td>
<td>37.6-63.5</td>
<td>623.4-1354</td>
</tr>
<tr>
<td></td>
<td>GMT</td>
<td>33.3</td>
<td>19.1</td>
<td>4.3</td>
<td>82.8</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>23.4-47.3</td>
<td>14.0-26.1</td>
<td>3.4-5.4</td>
<td>59.7-114.8</td>
</tr>
<tr>
<td>≥60</td>
<td>Seropositivity n/N</td>
<td>38/41</td>
<td>39/42</td>
<td>15/42</td>
<td>40/42</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
<td>90.5</td>
<td>92.9</td>
<td>35.7</td>
<td>95.2</td>
</tr>
<tr>
<td></td>
<td>GMU</td>
<td>134.1</td>
<td>104.1</td>
<td>32.4</td>
<td>300.5</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>89.2-201.6</td>
<td>71.8-151.0</td>
<td>25.1-41.8</td>
<td>203.5-443.6</td>
</tr>
<tr>
<td></td>
<td>GMT</td>
<td>20.8</td>
<td>14.7</td>
<td>2.9</td>
<td>36.5</td>
</tr>
<tr>
<td></td>
<td>95% CI</td>
<td>13.6-31.9</td>
<td>10.3-21.0</td>
<td>2.4-3.5</td>
<td>25.3-52.7</td>
</tr>
</tbody>
</table>

GMT: Geometric mean titer; GMU: Geometric mean units.
A

Total enrolled individuals (N = 2,302)

Total vaccinated individual who received two doses (N = 2,263)

Total individual belonging to the immunogenicity branch (N = 450)

Individuals vaccinated in a 0-28 schedule (N = 244)

Total individual vaccinated with follow up to six months (N = 218)

Total individual vaccinated with follow up to the booster dose (N = 186)

Analyzed individuals by sVNT (N = 77)

Analyzed individuals by ELISPOT and Flow cytometry (N = 33)

B
Pre-immune 28 days
1st dose 2nd dose 2nd dose 2nd dose 3rd dose
+ 2 weeks + 4 weeks + 20 weeks + 4 weeks